CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
Zidovudine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000625
NCT00000625Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Aug 31, 2001·Updated Nov 2, 2021

In Brief

A Phase 2 clinical trial evaluating Zidovudine, Zalcitabine, and 1 other intervention for HIV Infections. Completed, across 58 sites in 3 countries.

Detailed Summary

To determine the efficacy and safety of zidovudine ( AZT ) versus didanosine ( ddI ), AZT plus ddI, and AZT plus zalcitabine ( ddC ) in preventing disease progression in HIV-infected patients with CD4 counts of 200-500 cells/mm3.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesPuerto Rico, Tanzania, United States
CollaboratorsBristol-Myers Squibb, Glaxo Wellcome

Timeline

Phase 2CompletedFinished
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 31, 2001
Study CompletionNov 1, 1995
TodayJul 2, 2026
Posted 24.8 years ago

Interventions

Zidovudinedrug

Zalcitabinedrug

Didanosinedrug